Pyridoxamine (BioStratum).

Name: Pyridoxamine (BioStratum).
Creator: Nick, Giannoukakis
Keywords: 0301 basic medicine, Glycation End Products, Advanced, 03 medical and health sciences, Clinical Trials as Topic, Animals, Humans, Diabetic Nephropathies, Pyridoxamine, 3. Good health

Nick, Giannoukakis

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2005

Data sources: Europe PubMed Central

Pyridoxamine (BioStratum).

descriptionPublicationkeyboard_double_arrow_right Article 05 Dec 2005 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 6 (issn: 1472-4472,

Copyright policy )

Authors: Nick, Giannoukakis;

pmid: 15898348

Pyridoxamine (BioStratum).

- Summary
- Subjects
- Metrics

Abstract

BioStratum is developing pyridoxamine (Pyridorin), an advanced glycation end-product (AGE) inhibitor, for the potential prevention of diabetic nephropathy. By January 2004, phase II trials had been completed.

Related Organizations

University of Pittsburgh
United States

Keywords

Glycation End Products, Advanced, Clinical Trials as Topic, Animals, Humans, Diabetic Nephropathies, Pyridoxamine

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	11
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average